Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,096.00
Bid: 11,850.00
Ask: 12,400.00
Change: 0.00 (0.00%)
Spread: 550.00 (4.641%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,096.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Thu, 11th Apr 2024 17:07

Outlook hike sends Ambu shares up

*

AstraZeneca rises on plans to hike annual dividend

*

Lufthansa extends suspension of flights to Tehran

*

STOXX 600 off 0.4%

April 11 (Reuters) - Europe's benchmark stock index fell to a one-month low on Thursday, as banks took a hit after the European Central Bank held rates steady but signalled imminent cuts, while Deutsche Telekom dropped to a five-month low on trading ex-dividend.

The ECB maintained interest rates at record high as expected, but signalled it may soon start to cut them, even as investors question whether stubborn U.S. inflation will stop the Federal Reserve from following close behind.

The pan-European STOXX 600 closed 0.4% lower in volatile trade, with the banking sector taking the biggest hit, falling 2.4% and notching its steepest one-day drop in over eight months.

The indexes of top economies in the currency union such as Germany, France, Italy and Spain were also down between 0.3% to 1.2%.

"The ECB's decision to update its guidance suggests that an interest rate cut at the next meeting in June is very likely," Jack Allen-Reynolds, deputy chief euro zone economist at Capital Economics wrote.

"We expect the Bank to reduce the deposit rate from 4% currently to 3% by the end of the year."

The telecoms sector also shed 2.1%, dragged down by a 6.2% drop in Deutsche Telekom as the company traded ex-dividend.

Also denting equities were higher euro zone bond yields as expectations for a higher-for-longer scenario for U.S. interest rates more than offset the ECB remarks.

Investors also parsed a cooler-than-expected March producer inflation data in the United States.

After a lacklustre week, the STOXX 600 had hit a one-month low on Wednesday after a hot U.S. inflation report sparked concerns on the timeline for the Federal Reserve's first rate cut, while raising expectations that the ECB could lower rates before its U.S. counterpart.

Among other sectors, utilities and healthcare were among the rare bright spots, up 0.5% each.

As for individual stocks, Ambu climbed 4.6% after the Danish maker of single-use endoscopy solutions hiked its full-year outlook and posted preliminary second-quarter financials.

Lufthansa dropped 2.7% after the German carrier extended a suspension of its flights to Tehran, with the Middle East on alert for Iranian retaliation for a suspected Israeli airstrike on the country's embassy in Syria.

Idorsia postponed its 2023 and first-quarter results publication, sending the Swiss biotech firm's shares down 26.4%.

AstraZeneca rose 2.1% after the drugmaker said it planned to increase its annual dividend by 7% for 2024. (Reporting by Johann M Cherian, Ozan Ergenay and Ankika Biswas; Editing by Shounak Dasgupta, Arun Koyyur and Alison Williams)

More News
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.